Half Of Medical Research Might Be Missing Key Biological Differences

You’ve probably seen it before. A new study comes out with a clear takeaway, a promising treatment, or a bold claim about what works. It gets summarized into a headline, shared widely, and slowly becomes part of how we think about health. What rarely makes it into that conversation is another (arguably more important) question. 

Who, exactly, did this work for?

It’s easy to assume that a finding applies broadly unless told otherwise. But biology doesn’t always cooperate with that assumption. Men and women can experience the same disease differently, respond to the same medication in different ways, and even report symptoms differently. When those differences aren’t accounted for early on, they don’t magically correct themselves later.

To understand how well research is actually accounting for sex differences, scientists analyzed 574 studies published between 2017 and 2024, all tied to major grants from the National Institutes of Health. These weren’t small or obscure projects. They represent a large share of the research that shapes clinical care and future drug development.

The first layer looked promising. About 61% of studies included both men and women, or both male and female animals. That’s a meaningful shift from decades of male-dominated research. But inclusion was only part of the story. The more important question is what researchers did with that data. Did they actually compare outcomes between sexes, or just combine everything into one average?

That’s where things started to fall apart. Even when both sexes were included, only 44% of studies analyzed their results separately.

The gap was even more noticeable in early-stage research. Animal studies were less likely to include both sexes at all, which means potential differences can get missed long before treatments ever reach human trials.

When researchers combine data from men and women without analyzing them separately, they risk smoothing over differences that could change real-world outcomes.

That can show up in a few ways. A medication might appear effective overall but work better in one group than another. Side effects might look rare on paper, but be more common in women. Symptoms that are typical for men might dominate diagnostic criteria, leaving women underdiagnosed or misdiagnosed.

We’ve already seen examples of this in areas like heart disease and pain management, where women’s experiences didn’t fully match the original research. Those gaps weren’t always obvious at first. They became clear over time, often after years of clinical use.

This study doesn’t claim every condition needs sex-specific analysis at every stage. But it makes a strong case that skipping it by default limits what we can learn. If nearly half of the studies aren’t asking whether outcomes differ, we’re likely missing patterns that could make care more precise.

This isn’t a reason to distrust research. It’s a reason to read it a little more carefully. If you’re looking at a new study, it’s worth asking whether or not they analyze results by sex. The answer can change how relevant those findings are to you.

The more you look at health research, the more you realize how often “average” gets treated as “universal.” A result gets published, simplified, and shared as if it applies evenly to everyone, even when the underlying data might be telling a more nuanced story.

This research urges changes in the default habits in how studies are designed, analyzed, and reported. When researchers actually separate and compare outcomes, patterns start to emerge that were always there, just hidden in the aggregate.